- Conditions
- Fibromuscular Dysplasia of Arteries, Segmental Arterial Mediolysis, Spontaneous Coronary Artery Dissection, Atherosclerosis of Artery
- Interventions
- Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging, 3-D Volume Ultrasound
- Device · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 27
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatic Disease
- Interventions
- Sulfur Hexafluoride Microspheres
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Carotid Artery Plaque
- Interventions
- Contrast-enhanced ultrasound, Shear Wave Elastography, Ultrasound Examination
- Combination Product · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Necrotizing Enterocolitis of Newborn, Bowel Ischemic
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 18 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Malignant Tumor
- Interventions
- Contrast enhanced ultrasound with Lumason
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Recurrent Renal Cell Carcinoma, Renal Cell Carcinoma
- Interventions
- Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Computed Tomography, Magnetic Resonance Imaging, Electronic Health Record Review
- Drug · Procedure · Other
- Lead sponsor
- john eisenbrey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Developmental Dysplasia of the Hip
- Interventions
- Intraoperative contrast-enhanced ultrasound (CEUS), Lumason
- Diagnostic Test · Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 4 Months to 24 Months
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kidney Transplantation
- Interventions
- Lumason Contrast-Enhanced Ultrasound
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
- Interventions
- Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
- Diagnostic Test · Drug
- Lead sponsor
- Roderick Tan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Abdominal Trauma
- Interventions
- Focused Assessment with Sonography for Trauma (FAST), Bubble-Enhanced FAST (BEFAST)
- Diagnostic Test · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Lymphedema Arm
- Interventions
- Lumason, Optison, Definity
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Abdominal Injuries, Physical Abuse, Accidental Fall, Motor Vehicle Injury
- Interventions
- Contrast-Enhanced Ultrasound using Lumason
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 7 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Tumor
- Interventions
- Doppler ultrasound, Long Ensemble Angular-coherence Doppler [LEAD] ultrasound, Contrast-enhanced ultrasound (CEUS)
- Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Hepatocellular Carcinoma, Liver Cancer
- Interventions
- Lumason®
- Diagnostic Test
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
- Interventions
- Lumason, Sonazoid
- Diagnostic Test
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Appendicitis
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent, Ependymoma Recurrent, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, Brain Tumor Recurrent
- Interventions
- NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason, Nivolumab
- Device · Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Cirrhosis
- Interventions
- Contrast-Enhanced Ultrasound, Sulfur Hexafluoride Lipid Microspheres, Ultrasound
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hematoma
- Interventions
- CEUS or Contrast enhanced Ultrasound
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer, Contrast Enhanced Ultrasound
- Interventions
- Lumason
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Liver Biopsy
- Interventions
- Lumason 60.7Mg Powder for Injection, Placebos
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Crohn Disease
- Interventions
- Ultrasound Microbubble Contrast Agent, Ultrasound Imaging
- Drug · Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Proliferative Breast Disease
- Interventions
- Contrast Enhanced imaging, Lumason
- Diagnostic Test · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Liver Neoplasms
- Interventions
- Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Transarterial Chemoembolization, Medical Chart Review
- Drug · Procedure · Other
- Lead sponsor
- john eisenbrey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania